Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022165277 - NEAR INFRARED PHOTOIMMUNOTHERAPY (NIR-PIT) COMBINATION THERAPY TO TREAT CANCER

Publication Number WO/2022/165277
Publication Date 04.08.2022
International Application No. PCT/US2022/014448
International Filing Date 28.01.2022
IPC
A61K 47/68 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 41/0038
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41Medicinal preparations obtained by treating materials with wave energy or particle radiation ; ; Therapies using these preparations
0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
A61K 47/6851
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6851the antibody targeting a determinant of a tumour cell
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US]/[US]
Inventors
  • CHOYKE, Peter
  • KOBAYASHI, Hisataka
Agents
  • RYBAK, Sheree Lynn
  • SCOTT, Gregory K.
Priority Data
63/143,06829.01.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NEAR INFRARED PHOTOIMMUNOTHERAPY (NIR-PIT) COMBINATION THERAPY TO TREAT CANCER
(FR) POLYTHÉRAPIE À BASE DE PHOTO-IMMUNOTHÉRAPIE DANS LE PROCHE INFRAROUGE (NIR-PIT) POUR TRAITER LE CANCER
Abstract
(EN) Provided herein are methods of treating a subject with cancer using a therapeutically effective amount of one or more one or more tumor-specific antibody-IR700 molecules. The methods can further include administering to the subject a therapeutically effective amount of(a) one or more CTLA4 antibody-IR700 molecules, one or more PD-L1 antibody-IR700 molecules, or combinations thereof, (b) one or more reducing agents, (c) one or more immunoactivators, or combinations of a, b, and c, for example, either simultaneously or substantially simultaneously with the tumor-specific antibody-IR700 molecules, or sequentially (for example, within about 0 to 24 hours). The method also includes irradiating the subject or cancer cells in the subject (for example, a tumor or cancer cells in the blood) at a wavelength of 660 to 740 nm at a dose of at least 1 J/cm2. The use of one or more reducing agents can reduce edema resulting from treatment.
(FR) L'invention concerne des méthodes de traitement d'un sujet atteint d'un cancer faisant appel à une quantité thérapeutiquement efficace d'une ou plusieurs molécules d'anticorps-IR700 spécifiques d'une tumeur. Les méthodes peuvent en outre consister à administrer au sujet une quantité thérapeutiquement efficace de (a) une ou plusieurs molécules d'anticorps-IR700 anti-CTLA4, une ou plusieurs molécules d'anticorps-IR700 anti-PD-L1, ou des associations de celles-ci, (b) un ou plusieurs agents réducteurs, (c) un ou plusieurs immunoactivateurs, ou des associations de a, b et c, par exemple, simultanément ou sensiblement simultanément avec les molécules d'anticorps-IR700 spécifiques de la tumeur, ou consécutivement (par exemple, pendant environ 0 à 24 heures). La méthode consiste également à exposer le sujet ou les cellules cancéreuses chez le sujet (par exemple, une tumeur ou des cellules cancéreuses dans le sang) à un rayonnement d'une longueur d'onde de 660 à 740 nm à une dose d'au moins 1 J/cm2. L'utilisation d'un ou plusieurs agents réducteurs peut réduire un œdème résultant du traitement.
Latest bibliographic data on file with the International Bureau